Amy Raskopf - Evofem Biosciences VP Relations
Insider
Amy Raskopf is VP Relations of Evofem Biosciences
| Phone | 858 550 1900 |
| Web | https://www.evofem.com |
Evofem Biosciences Management Efficiency
The company has return on total asset (ROA) of (1.2475) % which means that it has lost $1.2475 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (3.8727) %, meaning that it created substantial loss on money invested by shareholders. Evofem Biosciences' management efficiency ratios could be used to measure how well Evofem Biosciences manages its routine affairs as well as how well it operates its assets and liabilities.Evofem Biosciences currently holds 125.74 M in liabilities with Debt to Equity (D/E) ratio of 8.72, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Evofem Biosciences has a current ratio of 0.16, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Evofem Biosciences until it has trouble settling it off, either with new capital or with free cash flow. So, Evofem Biosciences' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Evofem Biosciences sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Evofem to invest in growth at high rates of return. When we think about Evofem Biosciences' use of debt, we should always consider it together with cash and equity.
Similar Executives
| Showing other executives | INSIDER Age | ||
| Robert Lutz | iBio, Common Stock | 55 | |
| Melissa Berquist | iBio, Common Stock | N/A | |
| CPA CPA | Tonix Pharmaceuticals Holding | 50 | |
| Alexander Fudukidis | Affimed NV | N/A | |
| Randy Maddux | iBio, Common Stock | 63 | |
| Jason Davis | Virax Biolabs Group | 53 | |
| Cameron Shaw | Virax Biolabs Group | 37 | |
| Daniel MD | Tonix Pharmaceuticals Holding | N/A | |
| Seth MD | Tonix Pharmaceuticals Holding | 67 | |
| Denise Mueller | Affimed NV | 55 | |
| Stephen Kilmer | iBio, Common Stock | N/A | |
| Brian Kevany | Abeona Therapeutics | N/A | |
| John Cini | Sonnet Biotherapeutics Holdings | 72 | |
| Sharon McBrayer | Palisade Bio | N/A | |
| James Foster | Virax Biolabs Group | 40 | |
| Gideon Shapiro | Bright Minds Biosciences | N/A | |
| III CFA | Checkpoint Therapeutics | 46 | |
| Emer MBA | Bright Minds Biosciences | 58 | |
| MD FACP | Sonnet Biotherapeutics Holdings | 67 | |
| Andreas MD | Affimed NV | 64 | |
| Uwe Reusch | Affimed NV | N/A | |
Management Performance
| Return On Equity | -3.87 | ||||
| Return On Asset | -1.25 |
Evofem Biosciences Leadership Team
Elected by the shareholders, the Evofem Biosciences' board of directors comprises two types of representatives: Evofem Biosciences inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Evofem. The board's role is to monitor Evofem Biosciences' management team and ensure that shareholders' interests are well served. Evofem Biosciences' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Evofem Biosciences' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Justin File, Chief Officer | ||
| Katherine Atkinson, Chief Officer | ||
| Saundra Pelletier, Pres Chair | ||
| Amy Raskopf, VP Relations | ||
| Kathy GalloDoyle, VP Sales | ||
| Karina Fedasz, Head Devel |
Evofem Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right otc stock is not an easy task. Is Evofem Biosciences a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -3.87 | ||||
| Return On Asset | -1.25 | ||||
| Operating Margin | (5.41) % | ||||
| Current Valuation | 112.69 M | ||||
| Shares Outstanding | 121.22 M | ||||
| Shares Owned By Insiders | 0.28 % | ||||
| Shares Owned By Institutions | 0.57 % | ||||
| Number Of Shares Shorted | 8.68 M | ||||
| Price To Earning | (1.26) X | ||||
| Price To Book | 8.37 X |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any otc stock could be closely tied with the direction of predictive economic indicators such as signals in census. Note that the Evofem Biosciences information on this page should be used as a complementary analysis to other Evofem Biosciences' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Price Ceiling Movement module to calculate and plot Price Ceiling Movement for different equity instruments.
Other Consideration for investing in Evofem OTC Stock
If you are still planning to invest in Evofem Biosciences check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Evofem Biosciences' history and understand the potential risks before investing.
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Money Managers Screen money managers from public funds and ETFs managed around the world |